Research progress of gammadelta T cell-based immunotherapy

GammadeltaT cells are considered as linkage between innate and adaptive immune response, which recognize specific antigen without MHC-restriction. Vgamma9Vdelta2T cells, isolated from peripheral blood and tumor tissue, can be activated by non-peptide phosphoantigen through binding to its gammadeltaT...

Full description

Saved in:

Bibliographic Details
Published in:	Zhejiang da xue xue bao. Journal of Zhejiang University. Medical sciences. Yi xue ban Vol. 39; no. 4; p. 424
Main Authors:	Qiu, Fu-ming, Li, Zhong-peng, Huang, Jian
Format:	Journal Article
Language:	Chinese
Published:	China 01-07-2010
Subjects:	Humans Immunotherapy - methods Immunotherapy, Adoptive - methods Neoplasms - immunology Neoplasms - therapy Receptors, Antigen, T-Cell, gamma-delta - immunology T-Lymphocyte Subsets - immunology
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	GammadeltaT cells are considered as linkage between innate and adaptive immune response, which recognize specific antigen without MHC-restriction. Vgamma9Vdelta2T cells, isolated from peripheral blood and tumor tissue, can be activated by non-peptide phosphoantigen through binding to its gammadeltaTCR and proliferate under IL-2 stimulation. It has been shown that Vgamma9Vdelta2T cells possess anticancer activity against several types of tumor in vitro, as well as inhibit the growth of lymphoma, breast cancer and malignant melanoma in vivo. The phase I clinical trial of the application of Vgamma9Vdelta2T cells in treatment of lung cancer, renal cancer and prostate cancer demonstrated promising results. This review summarizes the recent advances in antigen recognition and activation of gammadeltaT cells, and the gammadeltaT cell-based immunotherapy for cancer treatment.
ISSN:	1008-9292